Abstract：
Results of the 2020 ASHP national survey of pharmacy practice in hospital settings pertaining to pharmacy operational changes implemented in response to the coronavirus disease 2019 (COVID-19) pandemic are presented.
Pharmacy directors at 1,437 general and children\'s medical/surgical hospitals in the United States were surveyed using a mixed-mode method of contact by email and mail. Survey completion was online.
The response rate was 18.7%. Seventy-three percent of hospitals implemented changes to hospital units, including 46% that increased intensive care unit bed capacity; 94% made changes to pharmacy supply chain acquisition, changes to products, and/or increased inventory. Staffing changes were implemented by 69% of hospitals, with the most common being staffing reductions (55%) and salary reductions (16%). Medication-use changes were implemented by 86% of hospitals, with treatment guidelines for COVID-19 treatment (79%) and opening compassionate use or investigational drug studies (55%) being the most common. Changes in sterile compounding processes were implemented by 84% of hospitals. Personal protective equipment (PPE) shortages led to 71% of hospitals modifying PPE use standards in sterile compounding. Eighty-seven percent of hospitals changed operational activities, such as changing medication return practices (56%), medication reconciliation processes (46%), intravenous medication recycling (38%), and discharge counseling (37%). Hospitals experienced shortages of many medications, including albuterol inhalers (60%), sedatives and anesthetic agents (58%), neuromuscular blockers (43%), corticosteroids (34%), cardiovascular agents (24%), investigational agents (24%), and dialysis solutions (6%).
The pharmacy profession responded to myriad threats to operations and patient care during the COVID-19 pandemic in 2020.
Pharmacy directors at 1,437 general and children\'s medical/surgical hospitals in the United States were surveyed using a mixed-mode method of contact by email and mail. Survey completion was online.
The response rate was 18.7%. Seventy-three percent of hospitals implemented changes to hospital units, including 46% that increased intensive care unit bed capacity; 94% made changes to pharmacy supply chain acquisition, changes to products, and/or increased inventory. Staffing changes were implemented by 69% of hospitals, with the most common being staffing reductions (55%) and salary reductions (16%). Medication-use changes were implemented by 86% of hospitals, with treatment guidelines for COVID-19 treatment (79%) and opening compassionate use or investigational drug studies (55%) being the most common. Changes in sterile compounding processes were implemented by 84% of hospitals. Personal protective equipment (PPE) shortages led to 71% of hospitals modifying PPE use standards in sterile compounding. Eighty-seven percent of hospitals changed operational activities, such as changing medication return practices (56%), medication reconciliation processes (46%), intravenous medication recycling (38%), and discharge counseling (37%). Hospitals experienced shortages of many medications, including albuterol inhalers (60%), sedatives and anesthetic agents (58%), neuromuscular blockers (43%), corticosteroids (34%), cardiovascular agents (24%), investigational agents (24%), and dialysis solutions (6%).
The pharmacy profession responded to myriad threats to operations and patient care during the COVID-19 pandemic in 2020.
摘要：
介绍了2020年ASHP全国医院药房实践调查的结果，该调查涉及为应对2019年冠状病毒病（COVID-19）大流行而实施的药房运营变化。
使用电子邮件和邮件联系的混合模式方法，对美国1,437家普通和儿童内科/外科医院的药房主任进行了调查。调查完成在线。
有效率为18.7%。百分之七十三的医院对医院单位实施了变更,其中46%增加了重症监护病房床位容量；94%对药房供应链收购做出了改变，产品的变化，和/或增加库存。69%的医院实施了人员配置改革，最常见的是裁员(55%)和减薪(16%)。86％的医院实施了药物使用变更，最常见的是COVID-19治疗指南(79%)和开放体恤使用或研究性药物研究(55%)。84％的医院实施了无菌混合过程的更改。个人防护设备（PPE）短缺导致71％的医院修改了无菌复合中的PPE使用标准。87%的医院改变了业务活动，例如改变药物返还做法(56%)，药物和解过程（46%），静脉注射药物回收(38%)，和出院咨询(37%)。医院经历了许多药物短缺，包括沙丁胺醇吸入剂(60%)，镇静剂和麻醉剂（58％），神经肌肉阻滞剂（43%），皮质类固醇（34%），心血管药物（24%），研究人员（24%），和透析溶液(6%)。
在2020年COVID-19大流行期间，药学行业对手术和患者护理的无数威胁做出了回应。
使用电子邮件和邮件联系的混合模式方法，对美国1,437家普通和儿童内科/外科医院的药房主任进行了调查。调查完成在线。
有效率为18.7%。百分之七十三的医院对医院单位实施了变更,其中46%增加了重症监护病房床位容量；94%对药房供应链收购做出了改变，产品的变化，和/或增加库存。69%的医院实施了人员配置改革，最常见的是裁员(55%)和减薪(16%)。86％的医院实施了药物使用变更，最常见的是COVID-19治疗指南(79%)和开放体恤使用或研究性药物研究(55%)。84％的医院实施了无菌混合过程的更改。个人防护设备（PPE）短缺导致71％的医院修改了无菌复合中的PPE使用标准。87%的医院改变了业务活动，例如改变药物返还做法(56%)，药物和解过程（46%），静脉注射药物回收(38%)，和出院咨询(37%)。医院经历了许多药物短缺，包括沙丁胺醇吸入剂(60%)，镇静剂和麻醉剂（58％），神经肌肉阻滞剂（43%），皮质类固醇（34%），心血管药物（24%），研究人员（24%），和透析溶液(6%)。
在2020年COVID-19大流行期间，药学行业对手术和患者护理的无数威胁做出了回应。
